Business
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of pa
About this update from Alumis Inc.
[{"type":"image","alt":"Alumis Inc.; ACELYRIN, INC.","displaySize":"","headline":null,"caption":"Alumis Inc.; ACELYRIN, INC.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D1V_aGoKejvy_01T3BfhbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911","width":150,"height":39}},"lazy":false},{"type":"text","content":"Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet","length":102,"tagName":"p"},{"type":"text","content":"Boards unanimously recommend stockholders vote “FOR” the merger","length":63,"tagName":"p"},{"type":"text","content":"Transaction expected to be completed in second quarter of 2025","length":62,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, have jointly filed a definitive proxy statement/prospectus with the U.S. Securities and Exchange Commission in connection with the proposed merger of the two companies. The joint proxy statement/prospectus are being mailed to all Alumis and ACELYRIN stockholders entitled to vote.","length":759,"tagName":"p"},{"type":"text","content":"Each company will hold a respective Special Meeting of Stockholders virtually at 12:00 p.m. E.T. on Tuesday, May 13, 2025. The stockholders of record as of the close of business on April 1, 2025, will be entitled to vote at the respective special meetings of stockholders.","length":272,"tagName":"p"},{"type":"text","content":"With a team that has a successful track-record of developing innovative therapies and an extended financial runway, the transaction will unlock the value of the combined portfolio for current and future investors. Key highlights of the transaction:","length":248,"tagName":"p"},{"type":"lis...